ArticleFrontiers in immunology2026
Pre-transplant bone marrow lymphocyte subsets predict outcome after allogeneic stem cell transplantation.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Recent evidence has demonstrated that both donor- and recipient-derived immune cell subpopulations play a crucial role in various immune responses following allogeneic hematopoietic stem cell transplantation (HSCT). In this retrospective single center analysis, we investigated whether different lymphocyte subpopulations in the bone marrow (BM) of the recipient prior to HSCT might have an impact on outcome parameters after HSCT. Methods: BM aspirates of 140 patients > 18 years of age receiving a HSCT between 2008 and 2022 were analyzed. BM aspiration was performed within 3 months prior to HSCT. Median time from aspiration to HSCT was 14 days (range 8-104 days). Lymphocyte subpopulations included CD19 Results: High total lymphocytes > 37.35% (of leukocytes) correlated with an increased non-relapse mortality (NRM) at day 100 after HSCT, whereas high CD3 Conclusion: Recipient-derived lymphocyte subpopulations within the BM prior to HSCT comprise the prognostic potential to assess post-HSCT related outcome parameters. In summary, a shift towards humoral immunity with a BM characterized by a B cell enriched and T cell/NK cell depleted microenvironment appears to be associated with a lower risk for post-HSCT complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.